436 related articles for article (PubMed ID: 25583358)
1. CHEK2 mutations and the risk of papillary thyroid cancer.
Siołek M; Cybulski C; Gąsior-Perczak D; Kowalik A; Kozak-Klonowska B; Kowalska A; Chłopek M; Kluźniak W; Wokołorczyk D; Pałyga I; Walczyk A; Lizis-Kolus K; Sun P; Lubiński J; Narod SA; Góźdż S
Int J Cancer; 2015 Aug; 137(3):548-52. PubMed ID: 25583358
[TBL] [Abstract][Full Text] [Related]
2. The risk of gastric cancer in carriers of CHEK2 mutations.
Teodorczyk U; Cybulski C; Wokołorczyk D; Jakubowska A; Starzyńska T; Lawniczak M; Domagała P; Ferenc K; Marlicz K; Banaszkiewicz Z; Wiśniowski R; Narod SA; Lubiński J
Fam Cancer; 2013 Sep; 12(3):473-8. PubMed ID: 23296741
[TBL] [Abstract][Full Text] [Related]
3. Case report of a woman with monoclonal gammapathy and papillary thyroid carcinoma, diagnosed because of detection of CHEK2 (I157T) mutation in genetic examinations.
Lizis-Kolus K; Kowalska A; Kozak-Klonowska B; Siołek M; Słuszniak J; Lubiński J; Cybulski C
Endokrynol Pol; 2010; 61(5):502-6. PubMed ID: 21049466
[TBL] [Abstract][Full Text] [Related]
4. A risk of breast cancer in women - carriers of constitutional CHEK2 gene mutations, originating from the North - Central Poland.
Bąk A; Janiszewska H; Junkiert-Czarnecka A; Heise M; Pilarska-Deltow M; Laskowski R; Pasińska M; Haus O
Hered Cancer Clin Pract; 2014 Apr; 12(1):10. PubMed ID: 24713400
[TBL] [Abstract][Full Text] [Related]
5. Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium.
Muranen TA; Blomqvist C; Dörk T; Jakubowska A; Heikkilä P; Fagerholm R; Greco D; Aittomäki K; Bojesen SE; Shah M; Dunning AM; Rhenius V; Hall P; Czene K; Brand JS; Darabi H; Chang-Claude J; Rudolph A; Nordestgaard BG; Couch FJ; Hart SN; Figueroa J; García-Closas M; Fasching PA; Beckmann MW; Li J; Liu J; Andrulis IL; Winqvist R; Pylkäs K; Mannermaa A; Kataja V; Lindblom A; Margolin S; Lubinski J; Dubrowinskaja N; Bolla MK; Dennis J; Michailidou K; Wang Q; Easton DF; Pharoah PD; Schmidt MK; Nevanlinna H
Breast Cancer Res; 2016 Oct; 18(1):98. PubMed ID: 27716369
[TBL] [Abstract][Full Text] [Related]
6. Incidence of the
Gąsior-Perczak D; Kowalik A; Gruszczyński K; Walczyk A; Siołek M; Pałyga I; Trepka S; Mikina E; Trybek T; Kopczyński J; Suligowska A; Ślusarczyk R; Gonet A; Jaskulski J; Orłowski P; Chrapek M; Góźdź S; Kowalska A
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33530461
[TBL] [Abstract][Full Text] [Related]
7. Association of two mutations in the CHEK2 gene with breast cancer.
Bogdanova N; Enssen-Dubrowinskaja N; Feshchenko S; Lazjuk GI; Rogov YI; Dammann O; Bremer M; Karstens JH; Sohn C; Dörk T
Int J Cancer; 2005 Aug; 116(2):263-6. PubMed ID: 15810020
[TBL] [Abstract][Full Text] [Related]
8. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.
Cybulski C; Wokołorczyk D; Jakubowska A; Huzarski T; Byrski T; Gronwald J; Masojć B; Deebniak T; Górski B; Blecharz P; Narod SA; Lubiński J
J Clin Oncol; 2011 Oct; 29(28):3747-52. PubMed ID: 21876083
[TBL] [Abstract][Full Text] [Related]
9. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
[TBL] [Abstract][Full Text] [Related]
10. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.
Näslund-Koch C; Nordestgaard BG; Bojesen SE
J Clin Oncol; 2016 Apr; 34(11):1208-16. PubMed ID: 26884562
[TBL] [Abstract][Full Text] [Related]
11.
Brock P; Liynarachchi S; Nieminen TT; Chan C; Kohlmann W; Stout LA; Yao S; La Greca A; Jensen KE; Kolesar JM; Salhia B; Gulhati P; Hicks JK; Ringel MD
Thyroid; 2024 Apr; 34(4):477-483. PubMed ID: 38279823
[No Abstract] [Full Text] [Related]
12. CHEK2 mutations and HNPCC-related colorectal cancer.
Suchy J; Cybulski C; Wokołorczyk D; Oszurek O; Górski B; Debniak T; Jakubowska A; Gronwald J; Huzarski T; Byrski T; Dziuba I; Gogacz M; Wiśniowski R; Wandzel P; Banaszkiewicz Z; Kurzawski G; Kładny J; Narod SA; Lubiński J
Int J Cancer; 2010 Jun; 126(12):3005-9. PubMed ID: 19876921
[TBL] [Abstract][Full Text] [Related]
13. CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population.
Hallamies S; Pelttari LM; Poikonen-Saksela P; Jekunen A; Jukkola-Vuorinen A; Auvinen P; Blomqvist C; Aittomäki K; Mattson J; Nevanlinna H
BMC Cancer; 2017 Sep; 17(1):620. PubMed ID: 28874143
[TBL] [Abstract][Full Text] [Related]
14. A novel founder CHEK2 mutation is associated with increased prostate cancer risk.
Cybulski C; Huzarski T; Górski B; Masojć B; Mierzejewski M; Debniak T; Gliniewicz B; Matyjasik J; Złowocka E; Kurzawski G; Sikorski A; Posmyk M; Szwiec M; Czajka R; Narod SA; Lubiński J
Cancer Res; 2004 Apr; 64(8):2677-9. PubMed ID: 15087378
[TBL] [Abstract][Full Text] [Related]
15. Survival of bladder or renal cancer in patients with CHEK2 mutations.
Złowocka-Perłowska E; Dębniak T; Słojewski M; van de Wetering T; Tołoczko-Grabarek A; Cybulski C; Scott RJ; Lubiński J
PLoS One; 2021; 16(9):e0257132. PubMed ID: 34499690
[TBL] [Abstract][Full Text] [Related]
16. CHEK2 1100delC, IVS2+1G>A and I157T mutations are not present in colorectal cancer cases from Turkish population.
Bayram S; Topaktaş M; Akkız H; Bekar A; Akgöllü E
Cancer Epidemiol; 2012 Oct; 36(5):453-7. PubMed ID: 22521562
[TBL] [Abstract][Full Text] [Related]
17. Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer.
Domagala P; Wokolorczyk D; Cybulski C; Huzarski T; Lubinski J; Domagala W
Breast Cancer Res Treat; 2012 Apr; 132(3):937-45. PubMed ID: 21701879
[TBL] [Abstract][Full Text] [Related]
18. A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland.
Cybulski C; Wokołorczyk D; Huzarski T; Byrski T; Gronwald J; Górski B; Debniak T; Masojć B; Jakubowska A; van de Wetering T; Narod SA; Lubiński J
Breast Cancer Res Treat; 2007 Mar; 102(1):119-22. PubMed ID: 16897426
[TBL] [Abstract][Full Text] [Related]
19. Can selenium be a modifier of cancer risk in CHEK2 mutation carriers?
Gupta S; Jaworska-Bieniek K; Lubinski J; Jakubowska A
Mutagenesis; 2013 Nov; 28(6):625-9. PubMed ID: 24106007
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer risk is similar for CHEK2 founder and non-founder mutation carriers.
Leedom TP; LaDuca H; McFarland R; Li S; Dolinsky JS; Chao EC
Cancer Genet; 2016 Sep; 209(9):403-407. PubMed ID: 27751358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
